• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期慢性肺部疾病新生儿的表面活性剂替代治疗

Surfactant replacement in neonates with early chronic lung disease.

作者信息

Pandit P B, Dunn M S, Kelly E N, Perlman M

机构信息

Department of Paediatrics, University of Toronto Perinatal Complex, Ontario, Canada.

出版信息

Pediatrics. 1995 Jun;95(6):851-4.

PMID:7761208
Abstract

OBJECTIVE

To study the effect of a single dose of exogenous bovine surfactant on oxygen and ventilatory requirements of neonates with early chronic lung disease.

STUDY DESIGN

Prospective pilot study.

SETTING

Three regional neonatal intensive care units.

METHODS

Infants 7 to 30 days old with birth weights less than 1500 g were eligible if they required a fraction of inspired oxygen (FIO2) of more than 0.4, had stable ventilatory requirements for 24 hours before study entry, and showed diffuse haziness on chest radiographs. Those with patent ductus arteriosus or active infection or those receiving steroid therapy were excluded. After treatment with the surfactant, differences in FIO2 and the ventilator efficiency index were analyzed using the Wilcoxon signed rank test.

RESULTS

Ten patients were recruited. Median values (range): birth weight, 693 g (530 to 1100 g); gestation, 25 weeks (24 to 27 weeks); and postnatal age at study entry, 13 days (9 to 30 days). The FIO2 decreased significantly between 0 and 1 hour after surfactant administration, from a median (range) of 0.67 (0.47 to 0.88) to 0.39 (0.28 to 0.63). This effect was sustained for 24 hours (median FIO2, 0.36). Although the FIO2 subsequently increased to 0.49 (range, 0.35 to 0.88) at 72 hours, it was significantly lower than that entry before the study. There was a trend toward an increase in the ventilator efficiency index at 24 and 48 hours.

CONCLUSIONS

A single dose of surfactant is effective in reducing oxygen requirements in neonates with early chronic lung disease. Surfactant replacement may be useful adjunctive therapy in these neonates.

摘要

目的

研究单剂量外源性牛肺表面活性物质对早期慢性肺疾病新生儿氧需求和通气需求的影响。

研究设计

前瞻性初步研究。

研究地点

三个地区性新生儿重症监护病房。

方法

出生体重小于1500g、年龄7至30天的婴儿,若吸入氧分数(FIO2)大于0.4,在研究入组前通气需求稳定24小时,且胸部X线片显示弥漫性模糊,则符合入选标准。排除动脉导管未闭或有活动性感染或正在接受类固醇治疗的婴儿。使用肺表面活性物质治疗后,采用Wilcoxon符号秩检验分析FIO2和通气效率指数的差异。

结果

招募了10名患者。中位数(范围):出生体重693g(530至1100g);孕周25周(24至27周);研究入组时的出生后年龄13天(9至30天)。给予肺表面活性物质后0至1小时内,FIO2显著下降,中位数(范围)从0.67(0.47至0.88)降至0.39(0.28至0.63)。这种效果持续24小时(FIO2中位数为0.36)。尽管72小时时FIO2随后升至0.49(范围为0.35至0.88),但仍显著低于研究前的水平。在24小时和48小时时,通气效率指数有增加趋势。

结论

单剂量肺表面活性物质可有效降低早期慢性肺疾病新生儿的氧需求。肺表面活性物质替代治疗可能是这些新生儿有用的辅助治疗方法。

相似文献

1
Surfactant replacement in neonates with early chronic lung disease.早期慢性肺部疾病新生儿的表面活性剂替代治疗
Pediatrics. 1995 Jun;95(6):851-4.
2
Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment.孕龄小于30周新生儿的牛肺表面活性物质替代疗法:预防与治疗的随机对照试验
Pediatrics. 1991 Mar;87(3):377-86.
3
Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage.因肺出血导致呼吸功能恶化的新生儿的表面活性剂治疗
Pediatrics. 1995 Jan;95(1):32-6.
4
Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group.单剂量改良牛肺表面活性物质提取物(固尔苏)预防呼吸窘迫综合征的多中心试验。罗斯协作表面活性物质预防研究组
Pediatrics. 1990 Jun;85(6):1092-102.
5
The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome.普罗沃多中心早期高频振荡通气试验:改善呼吸窘迫综合征的肺部情况及临床结局
Pediatrics. 1996 Dec;98(6 Pt 1):1044-57.
6
Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial.早期地塞米松治疗对极低出生体重儿肺力学和慢性肺病的影响:一项随机对照试验。
Pediatrics. 1995 Apr;95(4):584-90.
7
Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation.对妊娠29至32周的新生儿预防性给予小牛肺表面活性物质提取物比早期治疗呼吸窘迫综合征更有效。
Pediatrics. 1993 Jul;92(1):90-8.
8
Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome.孕30至36周患有呼吸窘迫综合征的新生儿单剂量与多剂量表面活性剂替代疗法
Pediatrics. 1990 Oct;86(4):564-71.
9
Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.严重新生儿呼吸窘迫综合征的表面活性剂替代疗法:一项国际随机临床试验。欧洲协作多中心研究小组
Pediatrics. 1988 Nov;82(5):683-91.
10
Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study.产前地塞米松治疗联合人表面活性剂挽救治疗:一项随机安慰剂对照多中心研究。
Pediatrics. 1994 May;93(5):730-6.

引用本文的文献

1
Use of surfactant beyond respiratory distress syndrome, what is the evidence?除了呼吸窘迫综合征之外,还在哪些情况下使用表面活性剂?有哪些证据?
J Perinatol. 2024 Apr;44(4):478-487. doi: 10.1038/s41372-024-01921-7. Epub 2024 Mar 8.
2
Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide.接受吸入一氧化氮治疗的机械通气早产儿晚期表面活性剂治疗的随机试验
J Pediatr. 2016 Jan;168:23-29.e4. doi: 10.1016/j.jpeds.2015.09.031. Epub 2015 Oct 21.
3
Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?
2013 年外源性表面活性剂治疗:下一步是什么?未来我们应该何时以及如何治疗新生儿?
BMC Pediatr. 2013 Oct 10;13:165. doi: 10.1186/1471-2431-13-165.
4
Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.用于治疗肺部疾病的表面活性剂替代疗法的递送与性能。
Ther Deliv. 2013 Aug;4(8):951-80. doi: 10.4155/tde.13.72.
5
Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome.表面活性物质重复给药在呼吸窘迫综合征中的药代动力学和临床预测因子。
Intensive Care Med. 2011 Mar;37(3):510-7. doi: 10.1007/s00134-010-2091-2. Epub 2010 Dec 10.
6
Surfactants: past, present and future.表面活性剂:过去、现在与未来。
J Perinatol. 2008 May;28 Suppl 1(Suppl 1):S47-56. doi: 10.1038/jp.2008.50.
7
A risk-benefit assessment of drugs used for neonatal chronic lung disease.用于新生儿慢性肺病药物的风险效益评估。
Drug Saf. 2000 May;22(5):389-404. doi: 10.2165/00002018-200022050-00006.
8
Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative Surfactant Study Group.猪肺表面活性物质治疗重症胎粪吸入综合征。协作性肺表面活性物质研究组。
Eur J Pediatr. 1996 Dec;155(12):1047-51. doi: 10.1007/BF02532529.
9
New targets for surfactant replacement therapy: experimental and clinical aspects.表面活性剂替代疗法的新靶点:实验与临床方面
Arch Dis Child Fetal Neonatal Ed. 1996 Jul;75(1):F1-3. doi: 10.1136/fn.75.1.f1.